Targeted Antibiotics for Lower Respiratory Tract Infection with Corynebacterium striatum
Huan Zhang,Xiaojiao Tan,Zhen Zhang,Xuewei Yang,Lijie Wang,Meiqian Li,Dan Shi,Yao Li,Jianbo Li,Zhen Li,Xuelian Liao
DOI: https://doi.org/10.2147/IDR.S404855
2023-04-05
Infection and Drug Resistance
Abstract:Huan Zhang, 1, 2 Xiaojiao Tan, 1 Zhen Zhang, 1 Xuewei Yang, 1 Lijie Wang, 1 Meiqian Li, 1 Dan Shi, 1 Yao Li, 1 Jianbo Li, 1 Zhen Li, 3 Xuelian Liao 1, 4 1 Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of China; 2 Department of Critical Care Medicine, The Third People's Hospital of Chengdu, Chengdu, People's Republic of China; 3 Clinical Research Unit, First Maternity and Infant Hospital of Shanghai, Shanghai, People's Republic of China; 4 Department of Critical Care Medicine, West China Tianfu Hospital of Sichuan University, Chengdu, People's Republic of China Correspondence: Xuelian Liao, Department of Critical Care Medicine, West China Hospital, Sichuan University, No. 37, Guoxue Lane, Wuhou district, Chengdu, People's Republic of China, Tel +8613541023033, Email Purpose: To assess the impact of targeted antibiotic therapy on clinical outcomes of patients with lower respiratory tract (LRT) infection with Corynebacterium striatum (C. striatum). Methods: A new propensity score-inverse probability of treatment weighting (IPTW) cohort study was conducted by using 10-year data. The study included LRT infection patients with respiratory secretions cultured positive for C. striatum simultaneously. The primary outcome was all-cause hospital mortality; the secondary outcomes included hospital stay, ICU stay and ventilation time. The safety outcomes were drug-related serum creatinine (Cr) increase and thrombocytopenia. Results: A total of 339 patients were included in the cohort, and 84 (24.78%) initiated vancomycin or linezolid therapy. In the new IPTW cohort, targeted antibiotic therapy did not improve all-cause hospital mortality ( P =0.632), and the OR (95% CI) was 0.879 (0.519– 1.488). Moreover, targeted antibiotic therapy was not associated with hospital stay ( P =0.415), ICU stay ( P =0.945) or ventilation time ( P =0.885). The side effects of drug-related higher serum Cr ( P =0.044) and thrombocytopenic levels ( P =0.038) cannot be ignored. Conclusion: Clinical benefits by vancomycin or linezolid targeted against LRT infection with C. striatum were limited and with drug-related side effects. A prospectively designed study is needed to further confirm the results. Keywords: Corynebacterium striatum , lower respiratory tract infection, vancomycin, linezolid, all-cause mortality Corynebacterium striatum (C. striatum) is emerging as a possible cause for severe hospital-acquired pneumonia with high mortality rates, especially among immunocompromised patients. The information about targeted antibiotic therapy against C. striatum in lower respiratory tract infection is scarce. In this study, a new propensity score-inverse probability of treatment weighting (IPTW) cohort study was conducted by using 10-year relatively large amount of data. Our results did not show any improvement in all-cause hospital mortality, hospital stay, ICU stay or ventilation time of targeted antibiotic therapy against C. striatum, but with drug-related side effects of serum creatinine increase and thrombocytopenia. Meanwhile, in subgroup analysis, targeted antibiotic therapy against C. striatum improved the all-cause hospital mortality when APACHE II score was higher than 15. That is to say, clinical benefits by vancomycin or linezolid targeted against C. striatum in LRT infection were limited, and with drug-related side effects. This study provides new insights into understanding the treatment of C. striatum in lower respiratory tract infection. Lower respiratory tract infection (LRT) is consistently among the leading causes of morbidity and mortality worldwide. As a normal resident of the human skin and mucous membranes, including the respiratory tract, Corynebacterium striatum (C. striatum) has historically been considered a contaminant, mainly due to the difficulty in distinguishing between colonization and infection. 1 In the last few decades, an increasing number of cases and studies have reported that C. striatum is considered a pathogen in different types of infections, 2 even as an emerging multidrug-resistant nosocomial pathogen. 3,4 Giorgio Silva-Santana et al 5 conducted a worldwide survey of C. striatum human invasive infections and nosocomial outbreaks over 44 years (1976–2020). They found that C. striatum has been increasingly reported as the etiologic agent of community-acquired and nosocomial diseases, especially for patients with chronic disease, long hospital stays, long ICU stays, and the use -Abstract Truncated-
pharmacology & pharmacy,infectious diseases